Consequently, overcoming bypass resistance requires a deeper mechanistic understanding of signaling networks in lung cancer, which will inform the development of novel therapeutic strategies and improve the long-term efficacy of ALK-targeted treatments. This evidence concerns the gene ALK and lung carcinoma.